{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:19:16Z","timestamp":1793837956525,"version":"4.6.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejmech.2024.116129","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T22:04:12Z","timestamp":1704492252000},"page":"116129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["HDAC-targeting epigenetic modulators for cancer immunotherapy"],"prefix":"10.1016","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4894-2454","authenticated-orcid":false,"given":"Binbin","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3529-5892","authenticated-orcid":false,"given":"Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2316-692X","authenticated-orcid":false,"given":"Yao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9494-7876","authenticated-orcid":false,"given":"Zongbao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7677-0570","authenticated-orcid":false,"given":"Yingxing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3710-8077","authenticated-orcid":false,"given":"Xiaoting","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4527-9473","authenticated-orcid":false,"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0011-9910","authenticated-orcid":false,"given":"Zhenhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4434-0846","authenticated-orcid":false,"given":"Xiaopeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-6572","authenticated-orcid":false,"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116129_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejmech.2024.116129_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2174\/1389557522666220930154527","article-title":"Small-molecule drugs in immunotherapy","volume":"23","author":"Hao","year":"2023","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib3","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2024.116129_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121138","article-title":"The impact of microbiota on PD-1\/PD-L1 inhibitor therapy outcomes: a focus on solid tumors","volume":"310","author":"Najafi","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2024.116129_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ejmech.2018.08.028","article-title":"Recent advances in small molecule based cancer immunotherapy","volume":"157","author":"Cheng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115465","article-title":"Inside PD-1\/PD-L1,2 with their inhibitors","volume":"256","author":"Boisgerault","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with Nivolumab plus Ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkmate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116129_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-022-05375-7","article-title":"High-potency PD-1\/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells","volume":"13","author":"Dai","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2024.116129_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14728222.2019.1559829","article-title":"CD73 as a potential opportunity for cancer immunotherapy","volume":"23","author":"Ghalamfarsa","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2024.116129_bib10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1139\/cjpp-2014-0460","article-title":"Regulation of immunological and inflammatory functions by biotin","volume":"93","author":"Kuroishi","year":"2015","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116129_bib11","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/s41467-021-21410-1","article-title":"Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1","volume":"12","author":"Park","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116129_bib12","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116129_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","article-title":"Targeting the microenvironment in solid tumors","volume":"65","author":"Belli","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2024.116129_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101312","article-title":"HDAC inhibitors: targets for tumor therapy, immune modulation and lung diseases","volume":"16","author":"Shanmugam","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejmech.2024.116129_bib15","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1016\/j.apsb.2022.02.017","article-title":"Immunogenic hydrogel toolkit disturbing residual tumor \"seeds\" and pre-metastatic \"soil\" for inhibition of postoperative tumor recurrence and metastasis","volume":"12","author":"Zhou","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116129_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2024.116129_bib17","first-page":"85","article-title":"The timing of nutritional status determination: implications for interventions and growth monitoring","volume":"45","author":"Huttly","year":"1991","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.ejmech.2024.116129_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tranon.2019.10.001","article-title":"Targeting tumor microenvironment by small-molecule inhibitors","volume":"13","author":"Zhong","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejmech.2024.116129_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1141215","article-title":"The impact of microbiome dysbiosis on T cell function within the tumor microenvironment (TME)","volume":"11","author":"DiPalma","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2024.116129_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2024.116129_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-022-00866-3","article-title":"Tumor microenvironment: barrier or opportunity towards effective cancer therapy","volume":"29","author":"Tiwari","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejmech.2024.116129_bib22","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1093\/nar\/gkad631","article-title":"The HDAC6-RNF168 axis regulates H2A\/H2A.X ubiquitination to enable double-strand break repair","volume":"51","author":"Qiu","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2024.116129_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001696","article-title":"Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma","volume":"9","author":"Que","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejmech.2024.116129_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2024.116129_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116129_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/CAD.0b013e328012a5db","article-title":"Histone deacetylase inhibitors for epigenetic therapy of cancer","volume":"18","author":"Monneret","year":"2007","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejmech.2024.116129_bib27","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.2174\/0929867324666170801102124","article-title":"Histone deacetylase inhibitors in tumor immunotherapy","volume":"26","author":"Zhao","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib28","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.2174\/1568026619666181210152115","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"18","author":"Sun","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/13543776.2020.1725470","article-title":"Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)","volume":"30","author":"Zhao","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116129_bib30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2174\/138161208783885380","article-title":"Inhibitors of NAD+ dependent histone deacetylases (sirtuins)","volume":"14","author":"Neugebauer","year":"2008","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2024.116129_bib31","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.7150\/thno.86928","article-title":"Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer","volume":"13","author":"Lin","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2024.116129_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216121","article-title":"The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy","volume":"559","author":"Moran","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.116129_bib33","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2024.116129_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1244035","article-title":"A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma","volume":"13","author":"Selim","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116129_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112831","article-title":"Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment","volume":"208","author":"Peng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104420","article-title":"Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-gamma response in NK-T cell lymphoma","volume":"87","author":"Wen","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2024.116129_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914964","article-title":"Epigenetic modulators as therapeutic agents in cancer","volume":"24","author":"Patnaik","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116129_bib38","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","article-title":"Single inhibitors versus dual inhibitors: role of HDAC in cancer","volume":"8","author":"Roy","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2024.116129_bib39","first-page":"14","article-title":"Histone deacetylase inhibitor panobinostat benefits the therapeutic efficacy of oncolytic herpes simplex virus combined with PD-1\/PD-L1 blocking in glioma and squamous cell carcinoma Models","author":"Wu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2024.116129_bib40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2174\/138161208783885353","article-title":"Chemical origins of isoform selectivity in histone deacetylase inhibitors","volume":"14","author":"Butler","year":"2008","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2024.116129_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/187152012800228814","article-title":"Selective histone deacetylase inhibitors","volume":"12","author":"Pan","year":"2012","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib42","first-page":"377","article-title":"Update on the treatment of cutaneous T-cell lymphoma (CTCL): focus on vorinostat","volume":"1","author":"Duvic","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.ejmech.2024.116129_bib43","first-page":"11","article-title":"Pathological role of HDAC8: cancer and beyond","author":"Kim","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2024.116129_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106971","article-title":"Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma","volume":"88","author":"Han","year":"2020","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2024.116129_bib45","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3389\/fimmu.2018.01525","article-title":"Attenuation of rheumatoid inflammation by sodium butyrate through reciprocal targeting of HDAC2 in osteoclasts and HDAC8 in T cells","volume":"9","author":"Kim","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2024.116129_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6804","article-title":"A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma","volume":"13","author":"Yang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.116129_bib47","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","article-title":"HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116129_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010066","article-title":"HDAC inhibition to prime immune checkpoint inhibitors","volume":"14","author":"Borcoman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116129_bib49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.it.2011.04.001","article-title":"Histone deacetylases as regulators of inflammation and immunity","volume":"32","author":"Shakespear","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejmech.2024.116129_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-019-0517-0","article-title":"HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics","volume":"7","author":"Laino","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejmech.2024.116129_bib51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116129_bib52","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1038\/s41598-017-02608-0","article-title":"Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma","volume":"7","author":"Ritter","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116129_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2024.116129_bib54","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1021\/acs.jmedchem.8b01087","article-title":"Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants","volume":"61","author":"Marek","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib55","doi-asserted-by":"crossref","first-page":"18861","DOI":"10.1021\/jacs.2c05030","article-title":"Aza-SAHA derivatives are selective histone deacetylase 10 chemical probes that inhibit polyamine deacetylation and phenocopy HDAC10 knockout","volume":"144","author":"Steimbach","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116129_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102800","article-title":"Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity","volume":"299","author":"Cellupica","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib57","doi-asserted-by":"crossref","first-page":"11355","DOI":"10.1074\/jbc.M707362200","article-title":"Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity","volume":"283","author":"Schuetz","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib58","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1021\/acsmedchemlett.2c00272","article-title":"Fragment-based discovery of a novel, brain penetrant, orally active HDAC2 inhibitor","volume":"13","author":"Tamanini","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116129_bib59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature10728","article-title":"Structure of HDAC3 bound to co-repressor and inositol tetraphosphate","volume":"481","author":"Watson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116129_bib60","doi-asserted-by":"crossref","first-page":"26694","DOI":"10.1074\/jbc.M803514200","article-title":"Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain","volume":"283","author":"Bottomley","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib61","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/jm301431y","article-title":"The 2.5 A crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition","volume":"56","author":"Zhao","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib62","article-title":"Dual inhibitors of HDAC and other epigenetic regulators: a novel strategy for cancer treatment","volume":"263","author":"Shirbhate","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115673","article-title":"A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy","volume":"259","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105901","article-title":"Dual BET\/HDAC inhibition to relieve neuropathic pain: recent advances, perspectives, and future opportunities","volume":"173","author":"Romanelli","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.116129_bib65","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semcancer.2020.11.005","article-title":"Anticancer properties of chimeric HDAC and kinase inhibitors","volume":"83","author":"Biersack","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2024.116129_bib66","article-title":"The development of HDAC and tubulin dual-targeting inhibitors for cancer therapy","author":"Nie","year":"2023","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib67","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s12253-020-00834-y","article-title":"HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line","volume":"26","author":"Hegedus","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ejmech.2024.116129_bib68","first-page":"3832","article-title":"Emerging role of PD-L1 modification in cancer immunotherapy","volume":"11","author":"Hu","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116129_bib69","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.21037\/tcr-20-3415","article-title":"PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma","volume":"10","author":"Yang","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116129_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104595","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.116129_bib71","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1158\/2767-9764.CRC-22-0117","article-title":"Tumor cell-autonomous SHP2 contributes to immune suppression in metastatic breast cancer","volume":"2","author":"Chen","year":"2022","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ejmech.2024.116129_bib72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116129_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2020.11.007","article-title":"Allosteric SHP2 inhibitors in cancer: targeting the intersection of RAS, resistance, and the immune microenvironment","volume":"62","author":"Kerr","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116129_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225384","article-title":"Overcoming immune checkpoint therapy resistance with SHP2 inhibition in cancer and immune cells: a review of the literature and novel combinatorial approaches","volume":"15","author":"Tojjari","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116129_bib75","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1021\/acs.jmedchem.2c00866","article-title":"Discovery of Novel Src homology-2 domain-containing phosphatase 2 and histone deacetylase dual inhibitors with potent antitumor efficacy and enhanced antitumor immunity","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib76","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.semcdb.2022.09.009","article-title":"Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: new chances for sophisticated drug design and treatment optimization","volume":"154","author":"Biersack","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2024.116129_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112086","article-title":"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo","volume":"190","author":"Ojha","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib78","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.2174\/0929867328666210902145102","article-title":"Dual targeting strategies on histone deacetylase 6 (HDAC6) and heat shock protein 90 (Hsp90)","volume":"29","author":"Bonanni","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib79","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s10020-021-00375-3","article-title":"Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90","volume":"27","author":"Liu","year":"2021","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116129_bib80","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7150\/ijbs.18834","article-title":"Targeting HSP90-HDAC6 regulating network implicates precision treatment of breast cancer","volume":"13","author":"Yu","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2024.116129_bib81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jare.2022.06.009","article-title":"Rational design of synthetically tractable HDAC6\/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment","volume":"46","author":"Wu","year":"2023","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ejmech.2024.116129_bib82","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116129_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115746","article-title":"The application of PROTAC in HDAC","volume":"260","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V","article-title":"Modes of regulation of ubiquitin-mediated protein degradation","volume":"182","author":"Kornitzer","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejmech.2024.116129_bib85","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4155\/fmc-2021-0206","article-title":"Designing HDAC-PROTACs: lessons learned so far","volume":"14","author":"Fischer","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib86","first-page":"26","article-title":"Design, synthesis, and biological evaluation of HDAC degraders with CRBN E3 ligase ligands","author":"Lu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116129_bib87","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2024.116129_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040634","article-title":"Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116129_bib89","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2174\/1568026621666211015092047","article-title":"Advances in the design and development of PROTAC-mediated HDAC degradation","volume":"22","author":"Rodrigues","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010209","article-title":"Targeting histone deacetylases: opportunities for cancer treatment and chemoprevention","volume":"14","author":"Ruzic","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2024.116129_bib91","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1039\/D0CC03243C","article-title":"Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs","volume":"56","author":"Xiao","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2024.116129_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112800","article-title":"Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)","volume":"208","author":"Cao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib93","doi-asserted-by":"crossref","first-page":"12445","DOI":"10.1021\/acs.jmedchem.2c01149","article-title":"Developing HDAC4-selective protein degraders to investigate the role of HDAC4 in huntington's disease pathology","volume":"65","author":"Macabuag","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib94","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib95","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: how they were found and how to discover new ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.ejmech.2024.116129_bib96","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.bmcl.2018.05.057","article-title":"Development of the first small molecule histone deacetylase 6 (HDAC6) degraders","volume":"28","author":"Yang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116129_bib97","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1021\/acs.jmedchem.9b00516","article-title":"Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity","volume":"62","author":"Wu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib98","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s13238-018-0602-z","article-title":"Developing potent PROTACs tools for selective degradation of HDAC6 protein","volume":"10","author":"An","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2024.116129_bib99","doi-asserted-by":"crossref","first-page":"14848","DOI":"10.1039\/C9CC08509B","article-title":"Plasticity in designing PROTACs for selective and potent degradation of HDAC6","volume":"55","author":"Yang","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2024.116129_bib100","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.chembiol.2020.04.008","article-title":"A cell-based target engagement assay for the identification of cereblon E3 ubiquitin ligase ligands and their application in HDAC6 degraders","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116129_bib101","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1021\/acsmedchemlett.0c00046","article-title":"Development of selective histone deacetylase 6 (HDAC6) degraders recruiting von hippel-lindau (VHL) E3 ubiquitin ligase","volume":"11","author":"Yang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116129_bib102","doi-asserted-by":"crossref","first-page":"16860","DOI":"10.1021\/acs.jmedchem.2c01659","article-title":"Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with antileukemic activity","volume":"65","author":"Sinatra","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib103","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1039\/D2CC00272H","article-title":"Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)","volume":"58","author":"Chotitumnavee","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2024.116129_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147535","article-title":"Design, synthesis and biological characterization of histone deacetylase 8 (HDAC8) proteolysis targeting chimeras (PROTACs) with anti-neuroblastoma activity","volume":"23","author":"Darwish","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116129_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114544","article-title":"Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8","volume":"239","author":"Sun","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib106","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1021\/acs.jmedchem.2c00739","article-title":"Structure-based discovery of selective histone deacetylase 8 degraders with potent anticancer activity","volume":"66","author":"Huang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib107","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1039\/D0CC01485K","article-title":"PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes","volume":"56","author":"Smalley","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2024.116129_bib108","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1039\/D2MD00199C","article-title":"A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras","volume":"13","author":"Cross","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116129_bib109","series-title":"Proteolysis-targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1\u20133","author":"Roatsch M","year":"2020"},{"key":"10.1016\/j.ejmech.2024.116129_bib110","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","article-title":"Chemically induced degradation of Sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on Sirtuin rearranging ligands (SirReals)","volume":"61","author":"Schiedel","year":"2018","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T09:56:07Z","timestamp":1736848567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":110,"alternative-id":["S0223523424000096"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116129","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC-targeting epigenetic modulators for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116129"}}